Aventera Antibodies
Lund, SE · 1 known investors
Aventera Antibodies is a preclinical biotech developing a first-in-class precision immunotherapy — an engineered monoclonal antibody — against invasive Group A Streptococcal (iGAS) infections, with first-in-human trials planned for 2028. The therapy is intended to be paired with rapid Strep-A diagnostics to enable early clinical intervention.
BiotechDeep TechHealthtech
Founders & leadership
AI
Arman IzadiCEO & Founder
CG
Caitriona GrönbergHead of Preclinical
LW
Lena Wester RosenlöfHead of CMC
PN
Pontus NordenfeltChairman of the Scientific Advisory Board, Board of Directors, Founder